Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 775 of 885 entries
View as:

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT06618001 Org: User:
Start: 01/14/25 End: 08/15/28 Due: 08/15/29

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

Phase: N/A Priority: Normal
NCT ID: NCT06881251 Org: User:
Start: 02/26/25 End: 07/15/26 Due: 07/15/27

A Study of JNJ-89402638 for Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06663319 Org: User:
Start: 10/15/24 End: 07/19/28 Due: 07/19/29

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05242471 Org: User:
Start: 07/22/22 End: 11/05/29 Due: 11/05/30

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT06878404 Org: User:
Start: 02/21/25 End: 12/29/28 Due: 12/29/29

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

Phase: N/A Priority: Normal
NCT ID: NCT03451851 Org: User:
Start: 07/11/18 End: 12/18/26 Due: 12/18/27

A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02889367 Org: User:
Start: 09/12/16 End: 03/04/17 Due: 03/04/18

Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00473746 Org: User:
Start: 06/30/06 End: 12/31/12 Due: 12/31/13

A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03871816 Org: User:
Start: 04/22/19 End: 11/22/22 Due: 11/22/23

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

Phase: N/A Priority: Normal
NCT ID: NCT04068792 Org: User:
Start: 10/10/19 End: 05/15/21 Due: 05/15/22

A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT02846545 Org: User:
Start: 08/26/16 End: 01/05/21 Due: 01/05/22

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05112939 Org: User:
Start: 11/16/21 End: 05/23/24 Due: 05/23/25

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

Phase: N/A Priority: Normal
NCT ID: NCT02008279 Org: User:
Start: 12/31/13 End: 08/31/14 Due: 08/31/15

A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01267084 Org: User:
Start: 02/28/11 End: 11/30/12 Due: 11/30/13

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

Phase: N/A Priority: Normal
NCT ID: NCT02846532 Org: User:
Start: 11/16/16 End: 07/16/20 Due: 07/16/21

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

Phase: N/A Priority: Normal
NCT ID: NCT03891524 Org: User:
Start: 06/17/19 End: 04/06/21 Due: 04/06/22

A Pharmacokinetic Interaction Study Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02611518 Org: User:
Start: 04/05/16 End: 06/14/16 Due: 06/14/17

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

Phase: N/A Priority: Normal
NCT ID: NCT02877225 Org: User:
Start: 08/29/16 End: 11/11/16 Due: 11/11/17

Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants

Phase: N/A Priority: Normal
NCT ID: NCT02824315 Org: User:
Start: 05/31/16 End: 10/31/16 Due: 10/31/17

A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03953196 Org: User:
Start: 04/08/19 End: 12/26/19 Due: 12/26/20

Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT02715011 Org: User:
Start: 06/01/16 End: 03/26/21 Due: 03/26/22

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00103506 Org: User:
Start: 12/31/04 End: 06/30/14 Due: 06/30/15

To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants

Phase: N/A Priority: Normal
NCT ID: NCT01809353 Org: User:
Start: 07/31/13 End: 09/30/14 Due: 09/30/15

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

Phase: N/A Priority: Normal
NCT ID: NCT06514742 Org: User:
Start: 06/26/24 End: 04/24/25 Due: 04/24/26

A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03058419 Org: User:
Start: 03/14/17 End: 05/15/17 Due: 05/15/18